Increase in diabetes research fuelled by GLP-1s like Ozempic
Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials.
The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate cancer and type 2 diabetes.
The mid-year analysis indicates breast cancer could be the most researched disease area for four-years running, after topping the table last year.
“Following the success of therapies like Ozempic, it’s no surprise that type 2 diabetes research is being prioritised by biopharmaceutical companies. But with complex conditions with several comorbidities – like type 2 diabetes – sponsors looking to keep costs low and minimise protocol amendments will need to design protocols with higher degrees of precision,” said Dr Gen Li, President and Founder, Phesi.
A third of trials cancelled at Phase II
Phesi’s analysis also reveals that the rise in Phase II study attrition first identified by Phesi in 2022 is continuing. So far in 2024, 32% of trials were terminated during Phase II – a 56% increase on pre-pandemic levels.
High levels of cancellations at Phase II not only increase the costs of clinical development, but also have a knock-on effect on the rate at which new therapies reach patients.
“The concern is that the almost a third of trials cancelled at Phase II is becoming the new normal – driving up costs across the industry and delaying therapies from getting to market,” Dr Li added. “In the last two decades, medical advances have driven a shift towards precision medicine. Yet clinical development practices have struggled to adapt to more specific patient inclusion criteria and smaller patient pools.”
Dr Li also identifies new diversity requirements from regulators and investigators backing out from trials post Covid-19 as complicating factors.
He concluded: “The clinical development industry can turn the tide on rising attrition by beginning with the patient. By leveraging predictive analytics, sponsors can design protocols better aligned with the target patient population, and identify the best performing investigator sites with a higher level of precision.”
The full analysis can be found in this report: https://info.phesi.com/2024-midyear-most_studied
Diana Spencer, Senior Digital Content Editor, DDW
